1227917-52-3 Usage
General Description
(R)-3-(1-Methylethyl)-Morpholine HCl, also known as levomethadyl acetate hydrochloride, is a chemical compound used as a narcotic antagonist and anti-addictive agent. It is a synthetic opioid, and acts as a long-acting mu-opioid receptor agonist. (R)-3-(1-Methylethyl)-Morpholine HCl is primarily used in the treatment of opioid addiction and is often administered orally as a medication. It has a similar mechanism of action to other opioids, but has a longer duration of action, making it effective in reducing cravings and withdrawal symptoms in individuals with opioid dependence. However, due to the potential for abuse and addiction, it is tightly regulated and only available in certain medical settings under close supervision.
Check Digit Verification of cas no
The CAS Registry Mumber 1227917-52-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,7,9,1 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1227917-52:
(9*1)+(8*2)+(7*2)+(6*7)+(5*9)+(4*1)+(3*7)+(2*5)+(1*2)=163
163 % 10 = 3
So 1227917-52-3 is a valid CAS Registry Number.
InChI:InChI=1S/C7H15NO.ClH/c1-6(2)7-5-9-4-3-8-7;/h6-8H,3-5H2,1-2H3;1H/t7-;/m0./s1
1227917-52-3Relevant articles and documents
Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease
Fukunaga, Kenji,Sakai, Daiki,Watanabe, Kazutoshi,Nakayama, Kazuki,Kohara, Toshiyuki,Tanaka, Hiroshi,Sunada, Shinji,Nabeno, Mika,Okamoto, Masako,Saito, Ken-Ichi,Eguchi, Jun-Ichi,Mori, Akiko,Tanaka, Shinji,Inazawa, Keiko,Horikawa, Takashi
, p. 1086 - 1091 (2015)
We herein describe the results of further evolution of GSK-3β inhibitors for Alzheimer's disease from our promising compounds with in vivo tau phosphorylation inhibitory activity by oral administration. Introduction of a low alkyl group instead of the phenyl group at the 3-position of the morpholine moiety aiming to improve pharmacokinetic profiles resulted in potent low molecular weight GSK-3β inhibitors with good in vitro pharmacokinetic profiles, which also showed in vivo tau phosphorylation inhibitory activity by oral administration. Effect of the stereochemistry of the alkyl moiety is also discussed using docking models.
